SCHEMBL1795337

SCHEMBL1795337

CCOc1ccccc1C1(OC(=O)N2CCN(C3CCN(C)CC3)CC2)C(=O)N(S(=O)(=O)c2ccc(F)cc2)c2ccc(C#N)cc21

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 9/20 0.42
SLC6A9 P48067 2/20 0.39
APP P05067 1/20 0.38
ALK Q9UM73 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KCNH2 Q12809 1/20 0.35
MGLL Q99685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1796113 0.96 AVPR1B (0.39) AVPR1BSLC6A9APPPSEN1PSEN2
SCHEMBL1799057 0.95 AVPR1B (0.42) AVPR1BSLC6A9ALKALDH1A1LMNA
SCHEMBL1795051 0.95 AVPR1B (0.42) AVPR1BSLC6A9ALKALDH1A1LMNA
SCHEMBL1796879 0.94 AVPR1B (0.49) AVPR1BALDH1A1KDM4E
SCHEMBL1796177 0.93 AVPR1B (0.41) AVPR1BSLC6A9APPALKPSEN1
SCHEMBL1795105 0.93 AVPR1B (0.41) AVPR1BSLC6A9ALKALDH1A1LMNA
SCHEMBL1800246 0.92 AVPR1B (0.43) AVPR1BSLC6A9APPALKPSEN1
SCHEMBL1794835 0.92 AVPR1B (0.42) AVPR1BSLC6A9ALKKCNH2
Hydrochloric Acid SCHEMBL1799829 0.92 AVPR1B (0.41) AVPR1BALKALDH1A1LMNAKDM4E
SCHEMBL1796069 0.92 ALDH1A1 (0.43) AVPR1BSLC6A9ALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338590-B2 Substituted oxindole derivatives and medicaments containing the same ABBOTT GMBH & CO. KG (DE) 2012-12-25 US disclosed
US-20110257194-A1 SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME ABBOTT GMBH & CO. KG (DE) 2011-10-20 US disclosed
US-7951807-B2 Substituted oxindol derivatives and medicaments containing the same ABBOTT GMBH & CO. KG (DE) 2011-05-31 US disclosed
US-20090005397-A1 Substituted Oxindol Derivatives and Medicaments Containing the Same ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005397-A1 Substituted Oxindol Derivatives and Medicaments Containing the Same OXTR, AVPR2, AVPR1B AVPR1B 3/4885SLC6A9 3173/4885APP 1346/4885
US-20110257194-A1 SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME OXTR, AVPR2, AVPR1B AVPR1B 3/4885SLC6A9 3301/4885APP 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.